SEC Company Response from Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282) (SYRE) — Apr 4, 2016
Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
Date: April 4, 2016 · CIK: 0001636282 · Accession: 0001193125-16-529226
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205001
Letter
UBS Securities LLC
299 Park Avenue
New York, New York 10171
BMO Capital Markets Corp.
3 Times Square, 26th Floor
New York, New York 10036
Wells Fargo Securities, LLC
375 Park Avenue, 4th Floor
New York, New York 10152
April 4, 2016
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Suzanne Hayes
Mary Beth Breslin
Christina Thomas
Keira Nakada
Joel Parker
Re: Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-1
Registration File No. 333-205001
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Aeglea BioTherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Washington, D.C. time, on April 6, 2016, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Fenwick & West LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated March 28, 2016:
(i) Dates of distribution: March 28, 2016 through the date hereof
(ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4
(iii) Number of prospectuses furnished to investors: approximately 4,243
(iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 80.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
UBS SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP UBS Securities LLC 299 Park Avenue New York, New York 10171 BMO Capital Markets Corp. 3 Times Square, 26th Floor New York, New York 10036 Wells Fargo Securities, LLC 375 Park Avenue, 4th Floor New York, New York 10152 April 4, 2016 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Suzanne Hayes Mary Beth Breslin Christina Thomas Keira Nakada Joel Parker Re: Aeglea BioTherapeutics, Inc. Registration Statement on Form S-1 Registration File No. 333-205001 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Aeglea BioTherapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Washington, D.C. time, on April 6, 2016, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Fenwick & West LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated March 28, 2016: (i) Dates of distribution: March 28, 2016 through the date hereof (ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4 (iii) Number of prospectuses furnished to investors: approximately 4,243 (iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 80. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, UBS SECURITIES LLC BMO CAPITAL MARKETS CORP. WELLS FARGO SECURITIES, LLC Acting severally on behalf of themselves and the several Underwriters By: UBS SECURITIES LLC By: /s/ Lee Schechter Name: Lee Schechter Title: Executive Director By: /s/ Matt Schainker Name: Matt Schainker Title: Director By: BMO CAPITAL MARKETS CORP. By: /s/ Steven Tuch Name: Steven Tuch Title: Managing Director By: WELLS FARGO SECURITIES, LLC By: /s/ David Herman Name: David Herman Title: Director